The importance of folic acid in present medicine;Importancia del ácido fólico en la medicina actual

Revista Medica de Chile

Volumn 128, Issue 2, 2000, Pages 213-220

  Cortés M, Fanny ^a,b   Hirsch B, Sandra ^a   De La Maza C , María Pía ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b NONE   (Chile)

Author keywords

Cardiovascular diseases; Folic acid deficiency; Neural tube defects; Nutrition disorders

Indexed keywords

ANTIANEMIC AGENT; FOLIC ACID; HOMOCYSTEINE;

ADULT; CARDIOVASCULAR DISEASE; DIET SUPPLEMENTATION; FEMALE; FOLIC ACID DEFICIENCY; HUMAN; INFANT; METABOLISM; NEURAL TUBE DEFECT; NEWBORN; PREGNANCY; REVIEW;

ADULT; CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; FEMALE; FOLIC ACID; FOLIC ACID DEFICIENCY; HEMATINICS; HOMOCYSTEINE; HUMANS; INFANT; INFANT, NEWBORN; NEURAL TUBE DEFECTS; PREGNANCY;

EID: 0034137144     PISSN: 00349887     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. ROBERTS DF, CHÁVEZ J, COURT SDM. The genetic component of child mortality. Arch Dis Child 1970; 45: 33-8.
2. BAIRD PA, ANDERSON TW, NEWCOMBE HB, LOWRY RB. Genetic disorders in children and young adults: A population study. Am J Hum Genet 1988; 42: 677-93.
3. MEDICAL RESEARCH COUNCIL VITAMIN STUDY RESEARCH. Prevention of neural tube defects: Results of the Medical Research Council Vitamin Study. Lancet 1991; 338: 131-7.
4. CZEIZEL AE, DUDAS I. Prevention of the first ocurrence of neural tube defects by periconceptional vitamin supplementation. N Engl J Med 1992; 327: 1832-5.
5. SMITHELLS RW, SHEPPARD S, WILD J. Prevention of neural tube defects recurrences in York-shire: Final report. Lancet 1989; 2: 498-9.
6. WILD J, SUTLIFFE M, SCHORAH CJ. Prevention of neural tube defects. Lancet 350: 30-1.
7. WATKINS ML (1998): Efficacy of folic acid profhylaxis for the prevention of neural tube defects. Ment Ret Dev Dis Res Rev 1997; 4: 282-90.
8. CENTERS FOR DISEASE CONTROL AND PREVENTION. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR 1992; 41: 1-7.
9. CLARCK NAC, FISK NM. Compliance with the Department of Health recommendations: routine folate prophylaxis to prevent fetal neural tube defects. Br J Obstet Gynaecol 1994; 101: 709-10.
10. WALD N, BOWER C. Folic acid and the prevention of neural tube defects. BMJ 1995; 310: 1019-20.
11. ROMANO PS, WAITZMAN NJ, SCHEFFLER RM, PI RD. Folic acid fortification of grain: An economic analysis. Am J Public Health 1995; 85: 667-76.
12. FOOD AND DRUF ADMINISTRATION. Food Standards: Amendment of standards of identity for enriched grain products to require addition of folic acid. Fec Register 1996; 61: 8781-97.
13. WALD N, HACKSHAW A. Folic acid and prevention of neural tube defects. Lancet 1997; 350: 665.
14. CASTILLO C, ATALAH E, BENAVIDES X, URTEAGA C. Patrones alimentarios en población adulta de la Región Metropolitana. Rev Méd Chil 1997; 125: 283-9.
15. HALL JG. Genetics of neural tube defects. Met Ret Dev Dis Rev Res 1998; 4: 291-6.
16. UBBINK JB, CHRISTIANSON A, BESTER MJ, VAN ALLEN MI, VENTER PA, DELPORT R, BLOM HJ, VAN DER MERWE A, POTGIETER H, VERMAAK WJ. Folate status, homocysteine metabolism, and methylene tetrahydrofolate reductase genotype in rural South African blacks with a history of pregnancy complicated by neural tube defects. Metabolism 1999; 48: 269-74.
17. 12 alters the frequency of neural tube defects in Axd mutant mice. J Nutr 1993; 123: 27-34.
18. SHAW GM, VELIE EM, SCHAFFER D. Is dietary intake of methionine associated with a reduction in risk for neural tube defects-affected pregnancies? Teratology 1997; 56: 295-9.
19. STEEGERS-THEUNISSEN RPM, BOERS GHJ, TRIJBELS FJ, FENKELSTEIN JD, BLOM HJ, THOMAS CM ET AL. Maternal hyperhomocysteinemia: A risk factor for neural tube defects. Metabolism 1994; 43: 1475-80.
20. STEEGERS-THEUNISSEN RPM, BOERS GHJ, BLOM HJ, NIJHUIS JG, THOMAS CM, BORM GF, ESKES TK. Neural tube defects and elevated homocysteine levels in amniotic fluid. Am J Obstet Gynecol 1995; 172: 1436-41.
21. CZEIZEL AE. Reduction of urinary tract and cardiovascular defects by periconceptional multivitamin supplementation. Am J Med Genet 1996; 62: 179-83.
22. SHAW GM, LAMMER EJ, WASSERMAN CR ET AL. Risks of orofacial clefts in children born to women using multivitamin containing folic acid periconceptionally. Lancet 1995; 346: 393-6.
23. MYERSON M, PEARSON T. Management of cardiovascular risk factors: An integral part of the optimal care of the patients with atherosclerosis disease. Am Coll Cardiology 1996; 12: 16-21.
24. ROSENBERG LE, SCRIBER CR. Disorders of Amino acid metabolism. En Metabolic Control and Disease. Bondy PK, Rosenberg LE eds, Saunders, 1980.
25. KANG SS, WONG PWK, MALINOW R. Hyperhomocysteinemia as a risk factor for occlusive vascular disease. Annu Rev Nut 1992; 12: 279-98.
26. CLARKE R, DALY L, ROBINSON K, NAUGHTEN E, CAHALANE S, FOWLER B ET AL. Hyperhomcysteinemia: an independent risk factor for vascular disease. NEJM 1991; 324: 1149-55.
27. SELHUB J, JACQUES PF, BOSTOM AG, D'AGOSTINO RB, WILSON PW, BELANGER AJ ET AL. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. NEJM 1995; 332: 286-91.
28. BOUSHEY CJ, BERESFORD SA, OMENN GS, MOTULSKY AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. J Am Med Assoc 1995; 274: 1049-57.
29. NYGARD O, NORDREHAUG JE, REFSUM H, UELAND PM, FARSTAD M, VOLLSET SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. NEJM 1997; 337: 230-6.
30. 6 concentrations, risk factor for stroke, peripheral vascular disease and coronary artery disease. Circulation 1998; 97: 437-43.
31. VERHOFF P, KOK FJ, KRUYSSEN DA, SCHOUTEN EG, WITTEMAN JC, GROBBEE DE ET AL. Plasma total Homocysteine; B vitamins and risk of coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17: 989-95.
32. MALINOW MR. Homocysteine and arterial occlusive diseases. J Intern Med 1994; 236: 603-17.
33. ENGBERSEN AM, FRANKEN DG, BOERS GH, STEENS EM, TRIJBELS FJ, BLOM HJ. Thermolabile 5,10 methylentetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. A J Hum Genet 1995; 56: 142-50.
34. MAYER EL, JACOBSEN DW, ROBINSON K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996; 27: 517-27.
35. TAWAKOL A, OMLAND T, GERHARD M, WU JT, CREAGER MA. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997; 95: 1119-21.
36. DOMAGALA TB, UNDAS A, LIBURA M, SZCZEKLIK A. Pathogenesis of vascular disease in hyperhomocysteinaemia. J Cardiovasc Risk 1998;5:239-47.
37. LUBEC B, ARBEITER K, HOEGER H, LUBEC C. Increased cyclin dependent kinase in aortic tissue of rats fed homocysteine. Thromb Haemost 1996; 75: 542-5.
38. IKEDA U, IKEDA M, MINOTA S, SHIMADA K. Homocysteine increases nitric oxide synthesis in cytokine-stimulated vascular smooth muscle cells. Circulation 1999; 99; 1230-5.
39. ROLLAND PH, FRIGGI A, BARLATIER A, PIQUET P, LATRILLE V, FAYE MM, GUILLOU J. Hyperhomocysteinemia-induced vascular damage in the minipig. Captopril-hydrochlorothiazide combination prevents elastic alterations. Circulation 1995; 91: 1161-74.
40. BRATTSTRÖM L, LINDGREN A, ISRAELSSON B, ANDERSON A, HULTBERG B. Homocysteine and cysteine: determinants of plasma levels in middle aged and elderly subjects. J Intern Med 1994; 236: 633-41.
41. KANG SS, WONG PWK, NORUSIS M. Homocysteinemia due to folate deficiency. Metabolism 1987; 36: 458-62.
42. SCHWARTZ SM, SISCOVICK DS, MALINOW MR, ROSENDAAL FR, BEVERLY RK, HESS DL ET AL. Myocardial infarction in young women in relation to plasma total homcysteine, folate and a common variant in the methylenetetrahydrofolate reductase gene. Circulation 1997; 96: 412-7.
43. BUNOUT D, GARRIDO A, SUAZO M, KAUFFMANN R, VENEGAS P, HIRSCH S ET AL. Effects of a supplementation with folic acid and antioxidant vitamins on homocysteine levels and LDL oxidation in coronary patients. Aceptado en Nutrition.
44. UBBINK JB, HAYWARD VERMAAK WJ, VAN DER MERWE A, BECKER PJ, DELPORT R, POTGIETER HC. Vitamin requirements for the treatment of hyperhomocisteinemia in humans. J Nutr 1994; 124: 1927-33.
45. MEZZANO D, MUÑOZ X, MARTÍNEZ C, CUEVAS A, PANES O, ARANDA E ET AL. Vegetarians and cardiovascular risk factors: hemostasis, inflammatory markers and plasma homocysteine. Thromb Haemost 1999; 81: 913-7.
46. AZAM MANSOOR M, UELAND PM, SVARDAL AM. Redox status and protein binding of plasma homocysteine and other aminothiols in patients with hyperhomocysteinemia due to cobalamin deficiency. Am J Clin Nutr 1994; 59; 631-5.
47. UBBINK JB, HAYWARD VERMAAK WJ, VAN DER MERWE A, BECKER PJ. Vitamin B-12, vitamin B-6 and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr 1993; 57: 47-53.
48. 12 deficiency after gastric surgery. Ann Intern Med 1996; 124: 469-76.
49. BOERS GH, SMALS AG, TRIJBELS FJ, LEERMAKERS AI, KLOPPPENBORG PW. Unique efficiency of methionine metabolism in premenopausal women may protect against vascular disease in the reproductive years. J Clin Invest 1983; 72: 1971-6.
50. HLTBERG B, BERGLUND M, ANDERSSON A, FRANK A. Elevated plasma homocysteine in alcoholics. Alcoholism Clin Exp Res 1993; 17: 687-9.
51. WILCKEN DE, DUDMAN NP, TYRRELL PA, ROBERTSON MR. Folic acid lowers elevated homocysteine in chronic renal insufficiency possible implications for prevention of vascular disease. Metabolism 1988; 37: 697-701.